Följ
Gianpiero Fasola
Gianpiero Fasola
Direttore, Dipartimento di Oncologia, Presidio Ospedaliero Universitario, Azienda Sanitaria
Verifierad e-postadress på asufc.sanita.fvg.it
Titel
Citeras av
Citeras av
År
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with …
LS Schwartzberg, F Rivera, M Karthaus, G Fasola, JL Canon, JR Hecht, ...
Journal of clinical oncology 32 (21), 2240-2247, 2014
7672014
Measures of outcome in metastatic breast cancer: insights from a real-world scenario
M Bonotto, L Gerratana, E Poletto, P Driol, M Giangreco, S Russo, ...
The oncologist 19 (6), 608-615, 2014
2652014
Clinical advances in the development of novel VEGFR2 inhibitors
C Fontanella, E Ongaro, S Bolzonello, M Guardascione, G Fasola, ...
Annals of translational medicine 2 (12), 2014
2642014
Pattern of metastasis and outcome in patients with breast cancer
L Gerratana, V Fanotto, M Bonotto, S Bolzonello, AM Minisini, G Fasola, ...
Clinical & experimental metastasis 32, 125-133, 2015
2032015
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
M Schirripa, F Bergamo, C Cremolini, M Casagrande, S Lonardi, G Aprile, ...
British journal of cancer 112 (12), 1921-1928, 2015
1712015
Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B
F Menichetti, A Del Favero, P Martino, G Bucaneve, A Micozzi, ...
Annals of internal medicine 120 (11), 913-918, 1994
1701994
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 …
F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ...
Cancer 122 (4), 574-581, 2016
1342016
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients …
F Rivera, M Karthaus, JR Hecht, I Sevilla, F Forget, G Fasola, JL Canon, ...
International journal of colorectal disease 32, 1179-1190, 2017
1232017
Expression of periostin in human breast cancer
F Puglisi, C Puppin, E Pegolo, C Andreetta, G Pascoletti, F D’Aurizio, ...
Journal of clinical pathology 61 (4), 494-498, 2008
1112008
Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach
F Grossi, M Aita, C Defferrari, F Rosetti, A Brianti, G Fasola, O Vinante, ...
The oncologist 14 (5), 497-510, 2009
1012009
Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility …
G Fasola, O Belvedere, M Aita, T Zanin, A Follador, P Cassetti, S Meduri, ...
The oncologist 12 (10), 1215-1224, 2007
1002007
Italian nivolumab expanded access program in nonsquamous non–small cell lung cancer patients: results in never-smokers and EGFR-mutant patients
MC Garassino, AJ Gelibter, F Grossi, R Chiari, HS Parra, S Cascinu, ...
Journal of Thoracic Oncology 13 (8), 1146-1155, 2018
852018
Drug waste minimization as an effective strategy of cost-containment in oncology
G Fasola, G Aprile, L Marini, A Follador, M Mansutti, M Miscoria
BMC health services research 14, 1-7, 2014
832014
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
L Fornaro, S Cereda, G Aprile, S Di Girolamo, D Santini, N Silvestris, ...
British journal of cancer 110 (9), 2165-2169, 2014
832014
Drug waste minimisation and cost-containment in medical oncology: two-year results of a feasibility study
G Fasola, M Aita, L Marini, A Follador, M Tosolini, L Mattioni, M Mansutti, ...
BMC Health Services Research 8, 1-8, 2008
792008
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer
L Foltran, GD Maglio, N Pella, P Ermacora, G Aprile, E Masiero, ...
Future Oncology 11 (4), 629-640, 2015
772015
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme
U De Giorgi, G Cartenė, D Giannarelli, U Basso, L Galli, E Cortesi, ...
BJU international 123 (1), 98-105, 2019
762019
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients
D Basile, A Parnofiello, MG Vitale, F Cortiula, L Gerratana, V Fanotto, ...
Journal of cachexia, sarcopenia and muscle 10 (2), 368-377, 2019
742019
Molecular classifications of gastric cancers: Novel insights and possible future applications
SK Garattini, D Basile, M Cattaneo, V Fanotto, E Ongaro, M Bonotto, ...
World journal of gastrointestinal oncology 9 (5), 194, 2017
682017
Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with or without adjuvant chemotherapy in patients with resected stage IB to III MAGE-A3-positive non-small-cell …
JL Pujol, JF Vansteenkiste, TM De Pas, D Atanackovic, M Reck, ...
Journal of Thoracic Oncology 10 (10), 1458-1467, 2015
642015
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20